Clinical trials: Vector-Borne Diseases
Malaria
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants
This will be a double-blinded randomized controlled phase III trial of 300 HIV uninfected pregnant women and the children born to them. The study interventions will be divided into two phases.
- Trial name
- PROMOTE-BC1 (NCT02163447)
- Testing
- Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
- Where
- Uganda
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.
Malaria
Chemopreventive Therapy for Malaria in Ugandan Children
Young African children living in high transmission areas suffer the greatest burden of malaria. In most African countries, such as Uganda, the only current preventive measure against malaria in high transmission settings is the…
- Trial name
- PROMOTE-Chemop (NCT00948896)
- Testing
- trimethoprim-sulfamethoxazole (TS; TMP/SMX), sulfadoxine-pyrimethamine (SP), dihydroartemisinin-piperaquine (DP)
- Where
- Uganda
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chagas Disease
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease).
- Trial name
- NCT02625974
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- 25 sites in Argentina, Bolivia and 1 more
- Volunteers
- 330 people
- Sponsor
- Bayer
Plasmodium Falciparum Infection, Malaria
Anti-malaria MAb in Kenyan Children
The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective…
- Trial name
- NCT05400655
- Testing
- L9LS
- Where
- Kenya
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)
This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P.
- Trial name
- NCT01256658
- Testing
- COA566
- Where
- 3 sites in Burkina Faso
- Volunteers
- 14,075 people
- Sponsor
- Novartis
Malaria
Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers
The primary objective of this study is to compare the bioavailability of two formulations (tablets and granules for dispersion) of the antimalarial drug pyronaridine-artesunate [3:1] (Pyramax, PA) in healthy adults.
- Trial name
- NCT01868438
- Testing
- Pyronaridine-artesunate granules, Pyronaridine-artesunate tablets
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Chikungunya Virus Infection
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection.
- Trial name
- NCT03807843
- Testing
- V184
- Where
- Puerto Rico
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Dengue
A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
This descriptive study will evaluate the safety and immunogenicity of different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00370682
- Testing
- T-DEN F17, T-DEN F-19
- Where
- Thailand
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following…
- Trial name
- NCT02207816
- Testing
- Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline